Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03264794
Efficacy and Safety of Precision Therapy in Refractory Tumor
- Conditions
- Rare TumorRefractory Tumor
- Interventions
- Drug: OxazolidineDrug: PD-1/L1 inhibitor plus anti-angiogenic agent
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Baodong Qin
- Target Recruit Count
- 300
- Registration Number
- NCT03239015
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients
- Conditions
- 2-year Disease-Free Survival
- Interventions
- Drug: Oral Navelbine + Carboplatin
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 590
- Registration Number
- NCT03203590
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 66
- Registration Number
- NCT03170180
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Bone Metastasis on the Survival of Gefitinib Effective Patients
- Conditions
- Overal Survival, Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 265
- Registration Number
- NCT03157310
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT03122717
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Bioequivalence Study of Gefitinib Tablets Under Fed Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Hunan Kelun Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03050177
Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions
- Conditions
- Bioequivalence Study
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Hunan Kelun Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03050164
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
- Conditions
- Advanced Solid Tumors Which Are cMET-dependent
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03040973
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 50
- Registration Number
- NCT02976116
- Locations
- 🇨🇳
The First Hospital of Zhejiang University, Hangzhou, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.